再生障碍性贫血是常见的造血系统疾病,特别是重型再障病情凶险,死亡率高。目前,治疗再障的主要方法包括造血干细胞移植和免疫抑制疗法。近年来,随着免疫介导致病机制的深入研究及临床免疫抑制治疗经验的不断总结,免疫抑制治疗得到了充分肯定,并取得显著疗效。本文意在综述免疫抑制治疗再生障碍性贫血的现状。 Aplastic anemia is a common hematopoietic system disease, especially in patients with severe aplastic anemia and high mortality. Currently, the main treatment of aplastic anemia, including hematopoietic stem cell transplantation and immunosuppressive therapy. In recent years, with the immune-mediated pathogenesis in-depth study and clinical immunosuppressive treatment experience of continuous summary of immunosuppressive therapy has been fully affirmed and achieved significant results. This article is intended to review the current status of immunosuppressive therapy for aplastic anemia.